EU needs Europe-wide cascade testing to tackle FH, says expert

Promoted content

This article is part of our special report Cardiovascular disease and cholesterol.

Consultant Chemical Pathologist at Birmingham’s Queen Elisabeth Hospital Robert Cramb has stressed the importance of cross-country coordination in Europe to tackle Familial Hypercholesterolemia or FH, one of the commonest cardiovascular hereditable diseases in the world.

Speaking during the 2015 European Atherosclerosis Annual Congress in Glasgow, Cramb said that implementing a “cascade-screening programme across Europe” would allow to trace populations properly an initiate “adequately targeted” therapies.

“In the Netherlands there as been a very strong case to cascade strong people with FH. 1 in 250 of the population have the disease, so much more common than we previously recognised,” Cramb added.

The Congress, which mainly focused on Familial Hypercholesterolemia, gives experts the opportunity to look over basic science and clinical applications of cardiovascular diseases.

Subscribe to our newsletters